Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. - Wikidata - wikimedia - TriplyDB

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q34553839

about

Immunotherapy for advanced renal cell cancer Targeted therapy for advanced renal cell carcinoma Immunotherapy for advanced renal cell cancer SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer Axitinib for the management of metastatic renal cell carcinoma State of the science: an update on renal cell carcinoma Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Sequence of treatment in locally advanced and metastatic renal cell carcinoma Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer Circulating biomarkers in advanced renal cell carcinoma: clinical applications Sunitinib in the treatment of metastatic renal cell carcinoma Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience Immunotherapy for metastatic renal cell carcinoma.Renal cell carcinoma.Renal cell cancer: overview of the current therapeutic landscape.Current clinical trials testing the combination of immunotherapy with radiotherapy.Chemokines as therapeutic targets in renal cell carcinoma Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis.Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma.Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients.The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ.Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma.Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.Interleukin-22 suppresses the growth of A498 renal cell carcinoma cells via regulation of STAT1 pathway.Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.Novel anti-melanoma treatment: focus on immunotherapy.Renal cell carcinoma: molecular biology and targeted therapy Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.

P2860

Q24187300-2C6E8761-A8D5-47C4-89C2-302285E8AE41 Q24242946-331EFE27-A783-4081-8D6F-82D8B324CB88 Q24246777-6FED9D6D-3538-4B58-B1B4-32D2A8D61572 Q24339492-541F69CD-8DBF-4842-BC93-917BCF82907D Q24613720-2440A430-C28A-4FF2-BBBC-7BEE7A1CEEA0 Q24630685-5449183E-B3D6-4A6F-B951-48B2967CB7D0 Q26766240-64162205-27C0-4493-AB1A-204D95333226 Q26773653-33A996B7-043F-4B73-A6BA-EDC3C2464F72 Q26775769-049583E6-6B41-459D-9B75-198A6F2FD430 Q26852704-6B15D82C-6954-4201-A9CA-5A9BB0BA1548 Q27023770-E3455C48-ABBF-4CF2-BCDD-B5BCA56A6E94 Q28072057-78B9FEA0-99F2-4917-A860-8DE7A4B8DA1C Q28072166-C7C1E4A7-6F37-4008-A9A2-25CACE3B1C68 Q30234458-8034B0F5-C10E-4525-9E17-CA8BE6875092 Q30235364-DAF22028-B48A-43AD-9512-CD02E471B885 Q30248354-6015B949-7A9F-47D3-860C-CA7777CF7B65 Q30356447-B8249AEE-B290-401F-A4ED-0F72B6D46FFC Q30435873-981EBEE7-B345-43FC-BE6F-849B051ED147 Q31085777-E711377F-A131-447A-852B-BB939B126B43 Q33404547-5C079160-AE74-4791-B6F7-B75E85271334 Q33510328-B166C6AA-09B0-4931-8742-AE978BF23C3D Q33716744-2EC32BA7-AD3A-4782-9D5B-48FF790837B5 Q33762689-C925A3A6-7407-495C-9BE7-4255ED0E6FA8 Q33778275-DBAF15FB-BACF-4FB3-B3E7-8BFAA8FDA46C Q33792683-2458E6DE-31A6-4CC0-9B76-539DF7BD2786 Q33828919-622B2A85-50FC-4784-A666-B9B05D5AA339 Q33873731-5BBEE319-4BFE-43F5-8FE4-5F33538DF255 Q33916153-33B86B47-FEC0-4E4C-B43B-3B5F470E951D Q33978763-5DFFE533-2C18-4C02-83F4-7514B91C1147 Q34021843-7A5A50CB-EE9E-4EA0-971B-4553570962FE Q34081653-1572D953-4199-47AA-B6CC-F2F913BF9318 Q34111701-9A44763C-2692-4529-B8D7-FB02929CF8F8 Q34221846-91A2365D-0327-4095-994E-9EC0DD759C71 Q34253761-B30277E3-0C07-4B3E-8822-CBED59B0FD98 Q34309404-BF4A0A98-5E56-4E5F-9C3D-2FFEBA175D06 Q34513914-9460315D-7147-47E2-B8B3-E1331A3A1C84 Q34517532-91A869D9-D5FE-4EAC-BDD8-7CF4E647438B Q34571555-87CAAEC8-13E5-4A3A-A243-93DBE831F77A Q34608796-049DC25D-30B6-465A-AD48-57D9651CE54C Q34627828-C880A713-A309-478D-873D-F0DCCEE03A3C

P2860

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q34553839

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@ast

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@en

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@nl

type

label

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@ast

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@en

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@nl

prefLabel

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@ast

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@en

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@nl

P1433

Q34553839-6C0F401D-41CE-49A7-9792-B68F627995D1

P1476

Q34553839-BFD5DB15-F5DA-4AC5-AB00-A8ACA096EB95

P2093

Q34553839-11068B1E-D988-4B61-B2A9-D96ABC052E5D

Q34553839-11142478-4D15-4C5C-AA11-A7F7733EF7C0

Q34553839-2760908F-7FEC-42F3-B283-10D2A5750C10

Q34553839-34918214-10A3-4A61-84A5-A49D19CDB09E

Q34553839-38E065EE-6793-4876-BE9B-343BF9EA29F8

Q34553839-45410257-B51C-41BB-9B50-B59C78297987

Q34553839-599B01D1-234D-4C70-BD9B-D8E53AA9CE92

Q34553839-5F82759F-5F4B-4DCE-BD17-EC465C5099A5

Q34553839-7F3429FB-D41D-4F50-99A3-9B525445EAAB

Q34553839-8C6E6E68-E1E7-49B3-8E81-B16DC0CB8803

P304

Q34553839-1EE913AD-2C7D-481F-A688-5E733B2C1D83

P31

Q34553839-E774FA26-08BD-4FD6-8916-A721839FDCB5

P356

Q34553839-D04CEC97-CF83-43BE-9284-381EDEE08D74

P407

Q34553839-6D75C5C0-7CBD-4288-91FC-9AAD67768ACD

P433

Q34553839-698193B0-F2ED-4A9E-A8F3-C3DB4048137A

P478

Q34553839-61C8DDFC-E2B2-45E4-8DA4-A2A21E865320

P577

Q34553839-40F1CCE5-ABFD-48FF-AF54-D967701770EB

P5875

Q34553839-1A2E0ECB-91C1-450E-9FB4-62197215E969

P698

Q34553839-B479A73B-2A47-421B-9DC7-D4A6DBFBEB23

P921

Q34553839-0ac5bfe2-b967-479f-a122-dbbf980a6059

Q34553839-5764DC50-5F47-4703-9451-8C14D7918A0A

Q34553839-FF9242D0-D2B1-42FE-AEE9-AA338461B975

P356

JCO.2005.03.206

P1433

Journal of Clinical Oncology

P1476

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@en

P2093

Christopher P G Tretter

http://www.w3.org/2001/XMLSchema#string

David F McDermott

http://www.w3.org/2001/XMLSchema#string

Geoffery R Weiss

http://www.w3.org/2001/XMLSchema#string

James W Mier

http://www.w3.org/2001/XMLSchema#string

Janice P Dutcher

http://www.w3.org/2001/XMLSchema#string

Jared A Gollob

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Sosman

http://www.w3.org/2001/XMLSchema#string

John M Kirkwood

http://www.w3.org/2001/XMLSchema#string

John W Smith

http://www.w3.org/2001/XMLSchema#string

Joseph I Clark

http://www.w3.org/2001/XMLSchema#string

P304

133-141

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.03.206

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8106321

http://www.w3.org/2001/XMLSchema#string

P698

15625368

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial